NASDAQ:ARTV Artiva Biotherapeutics Q2 2026 Earnings Report $11.22 -0.05 (-0.44%) Closing price 08/10/2026 04:00 PM EasternExtended Trading$11.01 -0.21 (-1.84%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Artiva Biotherapeutics EPS ResultsActual EPS-$0.63Consensus EPS -$0.63Beat/MissMissed by -$0.00One Year Ago EPSN/AArtiva Biotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AArtiva Biotherapeutics Announcement DetailsQuarterQ2 2026Date8/6/2026TimeAfter Market ClosesConference Call DateThursday, August 6, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Artiva Biotherapeutics Earnings HeadlinesArtiva Biotherapeutics (NASDAQ:ARTV) Upgraded to "Hold" at Wall Street ZenAugust 8 at 1:19 AM | americanbankingnews.comArtiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business HighlightsAugust 6, 2026 | finance.yahoo.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.August 11 at 1:00 AM | Banyan Hill Publishing (Ad)Artiva Biotherapeutics Sets Deadline for 2026 MeetingJuly 22, 2026 | tipranks.comArtiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 17, 2026 | globenewswire.comMajor Stake Boost Signals Growing Confidence in Artiva BiotherapeuticsJune 29, 2026 | tipranks.comSee More Artiva Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Artiva Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artiva Biotherapeutics and other key companies, straight to your email. Email Address About Artiva BiotherapeuticsArtiva Biotherapeutics (NASDAQ:ARTV) is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches. Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors. By combining gene-editing technologies with optimized cell expansion processes, the company aims to enhance tumor targeting, persistence and safety profiles. Its platform supports rapid manufacturing and scalable production, potentially enabling broader patient access and faster clinical development timelines. Founded in 2016 and headquartered in Cambridge, Massachusetts, Artiva Biotherapeutics operates in key biopharma hubs across North America and Europe. The company’s management team brings collective expertise in immuno-oncology, cell therapy manufacturing and clinical development, positioning Artiva to advance its candidate programs through pivotal trials and, ultimately, regulatory approval.View Artiva Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat5 Stocks the Market Rewarded After Strong Earnings ResultsQuantum Earnings Week: Winners and Losers Are Finally EmergingMarketBeat Week in Review – 08/03 - 08/07Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of WarCloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in FocusIs Monster Beverage’s Best-Case Scenario Already Priced Into the Stock? Upcoming Earnings Cisco Systems (8/12/2026)Brookfield (8/13/2026)NU (8/13/2026)Applied Materials (8/13/2026)BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
